- Home
- ATGE vs BLCO Comparison
ATGE vs BLCO Comparison
Compare ATGE & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATGE
- BLCO
- Stock Information
- Founded
- ATGE 1987
- BLCO 1853
- Country
- ATGE United States
- BLCO Canada
- Employees
- ATGE N/A
- BLCO N/A
- Industry
- ATGE Other Consumer Services
- BLCO Ophthalmic Goods
- Sector
- ATGE Consumer Discretionary
- BLCO Health Care
- Exchange
- ATGE Nasdaq
- BLCO Nasdaq
- Market Cap
- ATGE 4.0B
- BLCO 4.0B
- IPO Year
- ATGE 1991
- BLCO 2022
- Fundamental
- Price
- ATGE $104.63
- BLCO $12.28
- Analyst Decision
- ATGE Buy
- BLCO Hold
- Analyst Count
- ATGE 3
- BLCO 12
- Target Price
- ATGE $101.67
- BLCO $18.64
- AVG Volume (30 Days)
- ATGE 477.3K
- BLCO 872.9K
- Earning Date
- ATGE 05-08-2025
- BLCO 04-30-2025
- Dividend Yield
- ATGE N/A
- BLCO N/A
- EPS Growth
- ATGE 94.71
- BLCO N/A
- EPS
- ATGE 5.35
- BLCO N/A
- Revenue
- ATGE $1,687,694,000.00
- BLCO $4,791,000,000.00
- Revenue This Year
- ATGE $12.77
- BLCO $6.43
- Revenue Next Year
- ATGE $6.04
- BLCO $5.59
- P/E Ratio
- ATGE $19.67
- BLCO N/A
- Revenue Growth
- ATGE 12.83
- BLCO 15.56
- 52 Week Low
- ATGE $45.18
- BLCO $10.46
- 52 Week High
- ATGE $112.44
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- ATGE 56.21
- BLCO 38.77
- Support Level
- ATGE $96.75
- BLCO $10.46
- Resistance Level
- ATGE $107.05
- BLCO $12.56
- Average True Range (ATR)
- ATGE 5.00
- BLCO 0.96
- MACD
- ATGE 0.37
- BLCO -0.19
- Stochastic Oscillator
- ATGE 83.41
- BLCO 32.91
About ATGE Adtalem Global Education Inc.
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.